Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1867

1.

Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.

[No authors listed]

Prescrire Int. 2013 Apr;22(137):99-101, 103-4. Review.

PMID:
23662321
4.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group.

Ann Intern Med. 2001 Feb 6;134(3):191-202.

PMID:
11177331
5.

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.

Robertson L, Jones LE.

Cochrane Database Syst Rev. 2017 Feb 9;2:CD001100. doi: 10.1002/14651858.CD001100.pub4. Review.

PMID:
28182249
6.

Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.

Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S, Kluger J, Makanji S, Ashaye A, White CM.

Pharmacotherapy. 2012 Sep;32(9):799-808. doi: 10.1002/j.1875-9114.2012.01106.x. Epub 2012 Jun 28. Review.

PMID:
22744711
7.

Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.

Holzheimer RG.

Eur J Med Res. 2004 Apr 30;9(4):225-39. Review.

PMID:
15210403
8.

Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

Andras A, Sala Tenna A, Crawford F.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD002001. doi: 10.1002/14651858.CD002001.pub2. Review.

PMID:
23076894
9.
10.

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.

Robertson L, Strachan J.

Cochrane Database Syst Rev. 2017 Feb 14;2:CD006771. doi: 10.1002/14651858.CD006771.pub3. Review.

PMID:
28195640
12.

Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.

van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR.

Thromb Haemost. 2009 Apr;101(4):762-9.

PMID:
19350123
13.
14.

Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.

[No authors listed]

Prescrire Int. 2005 Aug;14(78):127-32.

PMID:
16106594
15.

Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

Clin Ther. 2007 Nov;29(11):2395-405. Review.

PMID:
18158080
16.

[Evidence-based guidelines for prevention and therapy of venous thromboembolism].

Falciani M, Dilaghi B, Conti AA, Caciolli S, Gensini GF.

Minerva Cardioangiol. 2000 Dec;48(12 Suppl 1):27-35. Italian.

PMID:
11253337
17.
18.
19.
20.

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.

van Den Belt AG, Prins MH, Lensing AW, Castro AA, Clark OA, Atallah AN, Burihan E.

Cochrane Database Syst Rev. 2000;(2):CD001100. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001100.

PMID:
10796593

Supplemental Content

Support Center